Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

Small molecule modulators of cyclin-dependent kinases for cancer therapy

Oncogene volume 19, pages 6600–6606 (2000)Cite this article

Abstract

The majority of human malignancies have aberrancies in the Retinoblastoma (Rb) pathway. Loss in Rb function results from the phosphorylation and inactivation of Rb by the cyclin-dependent kinases (cdks), main regulators of cell cycle progression. Thus, modulators of cdks may have a role in the treatment of human malignancies. Flavopiridol, the first cdk modulator tested in clinical trials, demonstrates interesting preclinical features: cell cycle block, induction of apoptosis, promotion of differentiation, inhibition of angiogenic processes and modulation of transcriptional events. Initial clinical trials with infusional flavopiridol demonstrated activity in some patients with lymphomas and renal, colon gastric carcinomas. Main side effects were diarrhea and hypotension. Phase 2 trials with infusional flavopiridol, other schedules and combination with standard chemotherapies are ongoing. The second cdk modulator tested in clinical trials, UCN-01, is a PKC inhibitor that can also modulate cdk activity. Similar to flavopiridol, UCN-01 blocks cell cycle progression and promotes apoptosis. Moreover, UCN-01 may abrogate checkpoints induced by genotoxic stress due to inhibition of chk1 kinase. The first clinical trial of UCN-01 demonstrated very prolonged half-life (∼600 h), due to high binding affinity of UCN-01 to the human alpha-1-acid glycoprotein. Main side effects were headaches, vomiting, hypoxemia and hyperglycemia. Clinical activity was observed in some patients with melanoma and lymphoma. Trials of shorter infusions of UCN-01 or in combination with standard chemotherapeutic agents are ongoing. Although several important basic and clinical questions remain unanswered, development of cdk modulators is a reasonable strategy for cancer therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

Abbreviations

cdk:

cyclin-dependent kinase

DLT:

dose-limiting toxicity

MTD:

maximally tolerated dose

IP:

intraperitoneal

IV:

intravenous

PK:

pharmacokinetics

References

  • Achenbach T, Muller R and Slater EP. . 2000 J. Biol. Chem. 275: 32089–32097.

  • Akinaga S, Gomi K, Morimoto M, Tamaoki T and Okabe M. . 1991 Cancer Res. 51: 4888–4892.

  • Akinaga S, Nomura K, Gomi K and Okabe M. . 1993 Cancer Chemother. Pharmacol. 32: 183–189.

  • Akinaga S, Nomura K, Gomi K and Okabe M. . 1994 Cancer Chemother. Pharmacol. 33: 273–280.

  • Akiyama T, Shimizu M, Okabe M, Tamaoki T and Akinaga S. . 1999 Anticancer Drugs 10: 67–78.

  • Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M and Akinaga S. . 1997 Cancer Res. 57: 1495–1501.

  • Arguello F, Alexander M, Sterry J, Tudor G, Smith E, Kalavar N, Greene J, Koss W, Morgan D, Stinson S, Siford T, Alvord W, Labansky R and Sausville E. . 1998 Blood 91: 2482–2490.

  • Bennett S, Mani S, O'Reilly S, Wright J, Schilsky R, Vokes E and Grochow L. . 1999 Proceedings of the American Society of Clinical Oncology, Vol. 18 Atlanta, GA.

  • Bible KC and Kaufmann SH. . 1996 Cancer Res. 56: 4856–4861.

  • Bible KC and Kaufmann SH. . 1997 Cancer Res. 57: 3375–3380.

  • Brusselbach S, Nettelbeck DM, Sedlacek HH and Muller R. . 1998 Int. J. Cancer 77: 146–152.

  • Bunch RT and Eastman A. . 1996 Clin. Cancer Res. 2: 791–797.

  • Bunch RT and Eastman A. . 1997 Cell Growth Differ. 8: 779–788.

  • Busby EC, Leistritz DF, Abraham RT, Karnitz LM and Sarkaria JN. . 2000 Cancer Res. 60: 2108–2112.

  • Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E and Grever MR. . 1998 Blood 92: 3804–3816.

  • Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA and Senderowicz AM. . 1999 Cancer Res. 59: 4634–4641.

  • Carlson B, Pearlstein R, Naik R, Sedlacek H, Sausville E and Worland P. . 1996a Proceedings of the American Association for Cancer Research Vol. 37: p. 424.

  • Carlson BA, Dubay MM, Sausville EA, Brizuela L and Worland PJ. . 1996b Cancer Res. 56: 2973–2978.

  • Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM and Price DH. . 2000 J. Biol. Chem. 275: 28345–28348.

  • Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C and Stadler W. . 1999 Cancer Chemother. Pharmacol. 44: 81–87.

  • De Azevedo Jr WF, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E and Kim SH. . 1996 Proc. Natl. Acad. Sci. USA 93: 2735–2740.

  • De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M and Kim SH. . 1997 Eur. J. Biochem. 243: 518–526.

  • Dyson N. . 1998 Genes Dev. 12: 2245–2262.

  • Elledge SJ. . 1996 Science 274: 1664–1672.

  • Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha SO, Hare MJ and Lu X. . 1997 Proc. Natl. Acad. Sci. USA 94: 6380–6385.

  • Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg W, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T and Kobayashi S. . 1998 Cancer Res. 58: 3248–3253.

  • Grana X, De Luca A, Sang N, Fu Y, Claudio PP, Rosenblatt J, Morgan DO and Giordano A. . 1994 Proc. Natl. Acad. Sci. USA 91: 3834–3838.

  • Grana X and Reddy EP. . 1995 Oncogene 11: 211–219.

  • Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM and Piwnica-Worms H. . 2000 J. Biol. Chem. 275: 5600–5605.

  • Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ and Schultz PG. . 1998 Science 281: 533–538.

  • Guedez L, Quintanilla-Martinez L, Lahusen T, Davies T, Singh SS, Barotto N, Vistica D, Raffeld M, Sausville EA and Senderowicz AM. . 1999 Proceedings of Ninetieth Annual Meeting of the American Association of Cancer Research, Philadelphia, PA.

  • Hatakeyama M and Weinberg RA. . 1995 Prog. Cell Cycle Res. 1: 9–19.

  • Hsueh CT, Kelsen D and Schwartz GK. . 1998 Clin. Cancer Res. 4: 2201–2206.

  • Husain A, Yan XJ, Rosales N, Aghajanian C, Schwartz GK and Spriggs DR. . 1997 Clin. Cancer Res. 3: 2089–2097.

  • Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R and Sausville E. . 1992 J. Natl. Cancer Inst. 84: 1736–1740.

  • Kawakami K, Futami H, Takahara J and Yamaguchi K. . 1996 Biochem. Biophys. Res. Commun. 219: 778–783.

  • Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak Jr A and Slee AM. . 1999 Anticancer Res. 19: 959–968.

  • Kitada S, Zapata JM, Andreeff M and Reed JC. . 2000 Blood 96: 393–397.

  • Konig A, Schwartz GK, Mohammad RM, Al-Katib A and Gabrilove JL. . 1997 Blood 90: 4307–4312.

  • Lahusen J, Loaiza-Perez A, Sausville EA and Senderowicz AM. . 2000 Proceedings of Twentieth Annual Meeting of the American Association of Cancer Research. San Francisco, CA.

  • Lee HR, Chang TH, Tebalt III, MJ, Senderowicz AM and Szabo, E. . 1999 Int. J. Oncol. 15: 161–166.

  • Li Y, Bhuiyan M, Alhasan S, Senderowicz AM and Sarkar FH. . 2000a Clin. Cancer Res. 6: 223–229.

  • Li Y, Chinni SR, Senderowicz AM and Sarkar FH. . 2000b Int. J. Oncol. 17: 755–759.

  • Losiewicz MD, Carlson BA, Kaur G, Sausville EA and Worland PJ. . 1994 Biochem. Biophys. Res. Commun. 201: 589–595.

  • MacLachlan TK, Sang N and Giordano A. . 1995 Crit. Rev. Eukaryot. Gene Expr. 5: 127–156.

  • Meijer L and Kim SH. . 1997 Methods Enzymol. 283: 113–128.

  • Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L and Senderowicz AM. . 1999 Cancer Res. 59: 5433–5437.

  • Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E and Balm A. . 1995 Cancer Res. 55: 975–978.

  • Morgan DO. . 1997 Annu. Rev. Cell. Dev. Biol. 13: 261–291.

  • Okami K, Reed AL, Cairns P, Koch WM, Westra WH, Wehage S, Jen J and Sidransky D. . 1999 Oncogene 18: 3541–3545.

  • Park DS, Farinelli SE and Greene LA. . 1996 J. Biol. Chem. 271: 8161–8169.

  • Parker B, Kaur G, Nieves-Neira W, Taimi M, Kolhagen G, Shimizu T, Pommier Y, Sausville E and Senderowicz AM. . 1998 Blood 91: 458–465.

  • Patel V, Senderowicz AM, Pinto D, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA and Gutkind JS. . 1998 J. Clin. Invest. 102: 1674–1681.

  • Peng J, Zhu Y, Milton JT and Price DH. . 1998 Genes Dev. 12: 755–762.

  • Pines J. . 1995 Adv. Cancer Res. 66: 181–212.

  • Pollack IF, Kawecki S and Lazo JS. . 1996 J. Neurosurg. 84: 1024–1032.

  • Rickert P, Seghezzi W, Shanahan F, Cho H and Lees E. . 1996 Oncogene 12: 2631–2640.

  • Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge SJ. . 1997 Science 277: 1497–1501.

  • Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM and Abraham RT. . 1999 Cancer Res. 59: 4375–4382.

  • Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T and Kobayashi S. . 1998 Cancer Chemother. Pharmacol. 42: (Suppl) S54–S59.

  • Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck SG and Senderowicz A. . 1999 Pharmacol. Ther. 82: 285–292.

  • Schrump DS, Matthews W, Chen GA, Mixon A and Altorki NK. . 1998 Clin. Cancer Res. 4: 2885–2890.

  • Schwartz G, Farsi K, Maslak P, Kelsen D and Spriggs D. . 1997 Clin. Cancer Res. 3: 1467–1472.

  • Schwartz G, Kaubisch A, Saltz L, Ilson D, O'Reilly E, Barazzuol J, Endres S, Soltz M, Tong W, Spriggs D and Kelsen D. . 1999 Proceedings of the American Society of Clinical Oncology Vol. 18: Atlanta, GA, p. 160.

  • Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A and Sausville E. . 1996 Intern. J. Oncol. 9: 1143–1168.

  • Senderowicz A. . 2000 Leukemia in press.

  • Senderowicz A, Murgo A and Kalil N. . 2000a S-A—J. Cancer 3: 95–112.

  • Senderowicz AM. . 1999 Invest. New Drugs 17: 313–320.

  • Senderowicz AM, Headlee D, Lush R, Bauer K, Figg W, Murgo AS, Arbuck S, Inoue K, Kobashi S, Kuwabara T and Sausville E. . 1998a 10th National Cancer Institute-European Organization for Research on Treatment of Cancer Symposium Proceedings: Amsterdam, Holland.

  • Senderowicz AM, Headlee D, Lush R, Bauer K, Figg W, Murgo AS, Arbuck S, Inoue K, Kobashi S, Kuwabara T and Sausville E. . 1999 Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology Vol. 18: Atlanta: GA.

  • Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG and Sausville EA. . 1998b J. Clin. Oncol. 16: 2986–2999.

  • Senderowicz AM, Messmann R, Arbuck S, Headlee D, Zhai S, Murgo A, Melillo G, Figg W and Sausville E. . 2000b Proceedings of the Annual Meeting of the American Society of Clinical Oncology. New Orleans.

  • Senderowicz AM and Sausville EA. . 2000 J. Natl. Cancer Inst. 92: 376–387.

  • Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA and Worland PJ. . 1994 Mol. Pharmacol. 45: 1207–1214.

  • Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA and Worland PJ. . 1993 Cancer Res. 53: 2081–2086.

  • Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW and Pommier Y. . 1997 Cancer Res. 57: 4029–4035.

  • Shapiro G, Patterson A, Lynch C, Lucca J, Anderson I, Boral A, Elias A, Lu H, Salgia R, Skarin A, Panek-Clark C, McKenna R, Rabin M, Vasconcelles M, Eder P, Supko J, Lynch T and Rollins B. . 1999 Proceedings of the American Society of Clinical Oncology Vol. 18. Atlanta: GA.

  • Shenfeld M, Senderowicz AM, Sausville EA and Barrett KE. . 1997 Gastroenterology 112: 404.

  • Sherr CJ. . 1996 Science 274: 1672–1677.

  • Sherr CJ and Roberts JM. . 1999 Genes Dev. 13: 1501–1512.

  • Shimizu E, Zhao MR, Nakanishi H, Yamamoto A, Yoshida S, Takada M, Ogura T and Sone S. . 1996 Oncology 53: 494–504.

  • Singh SS, Sausville EA and Senderowicz AM. . 1999 Proceedings of the 19th Annual Meeting of the American Association of Cancer Research. Philadelphia: PA.

  • Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D and Vokes EE. . 2000 J. Clin. Oncol. 18: 371–375.

  • Takahashi I, Kobayashi E, Asano K, Yoshida M and Nakano H. . 1987 J. Antibiot. (Tokyo) 40: 1782–1784.

  • Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M and Tamaoki T. . 1989 J. Antibiot. (Tokyo) 42: 571–576.

  • Tamaoki T. . 1991 Methods Enzymol. 201: 340–347.

  • Thomas J, Cleary J, Tutsch K, Arzoomanian R, Alberti D, Simon K, Feierabend D, Morgan K and Wilding G. . 1997 Proceedings 88th Annual Meeting of the American Association of Cancer Research. San Diego: CA.

  • Tsuchida E and Urano M. . 1997 Int. J. Radiat. Oncol. Biol. Phys. 39: 1153–1161.

  • Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA and O'Connor P. . 1996 J. Natl. Cancer Inst. 88: 956–965.

  • Wang Q, Worland PJ, Clark JL, Carlson BA and Sausville EA. . 1995 Cell Growth Differ. 6: 927–936.

  • Wei P, Garber ME, Fang SM, Fischer WH and Jones KA. . 1998 Cell 92: 451–462.

  • Weinberg RA. . 1995 Cell 81: 323–330.

  • Werner J, Kelsen D, Karpeh M, Inzeo D, Barazzuol J, Sugarman A and Schwartz GK. . 1998 Proceedings of the American Society of Clinical Oncology Vol. 17. Los Angeles: CA.

  • Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM and Monks A. . 2000 Clin. Cancer Res. 6: 415–421.

  • Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O and Sausville EA. . 1993 Biochem. Pharmacol. 46: 1831–1840.

  • Wright J, Blatner GL and Cheson BD. . 1998 Oncology (Huntingt) 12: 1018, 1023–1024.

  • Yu L, Orlandi L, Wang P, Orr M, Senderowicz AM, Sausville EA, Silvestrini RA and O'Connor P. . 1998 J. Biol. Chem. 273: 33455–33464.

  • Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L and Sausville EA. . 1999 Cancer Res. 59: 2566–2569.

  • Zhang HS, Postigo AA and Dean DC. . 1999 Cell 97: 53–61.

Download references

Author information

Authors and Affiliations

  1. Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892-4340, Maryland, USA

    Adrian M Senderowicz

Authors
  1. Adrian M Senderowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Senderowicz, A. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19, 6600–6606 (2000). https://doi.org/10.1038/sj.onc.1204085

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204085

Keywords

Search

Advanced search

Quick links